You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 藥明生物盤中上漲5%,報於64.95港元

2022年2月25日9時54分,藥明生物(HK02269)盤中上漲5%,報於64.95港元,成交額達3.59億港元,換手率達到0.08%。

2月23日訊,俄烏地緣政治緊張局勢升級,但美國多項經濟數據勝預期。亞太區股市今天普遍隨美股期貨反彈,尤其是滬深股市高收回升0.9%-1.9%,港股、澳股、越南及印尼股市回升0.6%-0.9%,其中恆指在匯控(00005.HK)、美團(03690.HK)、比亞迪(01211.HK)、京東(09618.HK)、舜宇(02382.HK)及藥明生物(02269.HK)回升近3%-5%帶動,午後升幅曾擴至225點高見23,745,收23,660,回升140點。然而,菲股回吐1%,疫情嚴峻新加坡股市續軟。

2月14日,大和:予九毛九(09922)及友邦保險(01299)“買入”評級,均列爲首選股。2月10日,大摩:相信藥明生物(02269)未來60天股價將上升,續爲首選股。2月9日,瑞信:維持藥明生物(02269)“跑贏大市”評級,目標價降20.5%至120港元。

最新的財務數據顯示,公司於2021年2季度,營業收入44.07億人民幣,淨利潤18.83億人民幣;營業收入同比增加126.67%,毛利潤同比增加190.8%,淨利潤同比增加157.67%。

盈立趨勢長盈模型最近一次交易信號,2022年2月8日出現觀望信號,觸發價格爲62.25港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account